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Background. Simultaneous pancreas-kidney (SPK) transplantation is a proven option of treatment for patients with type 1 diabetes
mellitus (T1DM) and related end-stage renal disease. There is discrepancy between the results of different studies about the impact
of prolonged normalization of glucose metabolism achieved by SPK on the course of diabetic complications including severe forms
of diabetic neuropathy. The objective of the study was to evaluate the prevalence of cardiovascular autonomic neuropathy (CAN) in
patients undergoing SPK transplantation and its evolution 10 years after transplantation.Methods. Prospective study of 81 patients
transplanted in a single center from year 2002 to 2015. Autonomic function was assessed using cardiovascular autonomic reflex
tests (CARTs). CARTs were made before SPK transplantation and during the follow-up. Evolution of tests after SPK
transplantation was evaluated by contrasting hypotheses (paired tests). Multiple testing was adjusted with the Benjamini-
Hochberg procedure with a false discovery rate of 10%. Results. 48 males and 33 females, mean age 37:4 ± 5:7 years, mean BMI
24:0 ± 3:4 kg/m2, and mean duration of diabetes 25:5 ± 6:5 years, received SPK transplantation. Ten years after SPK
transplantation, 56 patients re tained the pancreatic graft (42 of them with normofunctioning pancreas and 14 with low doses of
insulin therapy). These 42 patients were selected for the autonomic study. Before transplant procedure, all CART results were
abnormal. After SPK transplantation, paired test analysis showed an improvement of systolic blood pressure (SBP) response to
orthostasis at the 5th year after SPK (p = 0:03), as well as improvement of the Valsalva ratio at the 3rd (p < 0:001) and 5th
(p = 0:001) year after SPK. After correcting for the false discovery rate, all the variables of autonomic study reached significance
at different time points. Conclusions. Prevalence of CAN in patients who are candidates for SPK transplantation is high and is
generally advanced. SPK transplantation improves CAN with improved Valsalva ratio as the most precocious test.
1. Introduction
Diabetic neuropathy is a common microvascular complica-
tion of long-term diabetes mellitus (DM). Its etiopathogen-
esis is multifactorial, but hyperglycemia seems to be the
primary cause: increased accumulation of sorbitol and fruc-
tose in the nerves and decreased myoinositol and Na/K
ATPase activity. Other mechanisms such as hypoglycemia
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[1], immunological mechanisms (antiganglioside antibod-
ies), antiphospholipid antibodies, or microvascular insuffi-
ciency/ischemia are also involved in its etiopathogenesis [2].
Diabetic autonomic neuropathy (DAN) is a poorly stud-
ied complication of DM, despite its frequency and the signif-
icant negative impact it has on the survival and quality of life
of diabetic patients [3]. DAN usually appears in long-
standing diabetic patients, with poor metabolic control and
is associated with the presence of other complications [4].
Cardiovascular autonomic neuropathy (CAN) is the
most frequent autonomic complication in DM. CAN is
defined as an alteration of the cardiovascular response to var-
ious visceral reflexes and is associated with a significant
amount of the morbidity and mortality of diabetes. The liter-
ature shows a varying CAN prevalence depending on the cri-
teria used for diagnosis, the population studied, and the time
of DM evolution [5–8]: autonomic involvement varies in a
range from 2 to 95% in type 1 DM (T1DM) and 25 to 75%
in type 2 DM [5, 6] and up to around 90% in patients with
a long-standing type 1 DMwho are candidates for a pancreas
transplantation [7].
CAN usually manifests itself subclinically, characterized
by the alteration of cardiovascular reflexes such as resting
tachycardia, or clinically, less frequently, and generally man-
ifested as exercise intolerance, orthostatic hypotension, silent
myocardial infarction, and intraoperative cardiovascular lia-
bility [5, 9–12]. Orthostatic hypotension is the most incapac-
itating manifestation of autonomic failure and is a
consequence of reduced vasoconstriction of the splanchnic
and other peripheral vascular beds due to efferent sympa-
thetic vasomotor denervation [1]. As the symptoms and signs
for CAN are nonspecific, early diagnosis and follow-up
require special techniques based on heart rate (HR) variabil-
ity. Cardiovascular autonomic reflex tests (CARTs) or
“Ewing test” are considered the “Gold standard” [10–13].
All T1DM patients should be assessed for diabetic peripheral
neuropathy starting 5 years after diagnosis and at least annu-
ally thereafter [14].
On the other hand, pancreas transplantation is a proven
option of treatment for patients with T1DM and related
end-stage renal disease, who are candidates for kidney
transplantation. Three types of whole pancreas transplanta-
tion are described: simultaneous pancreas kidney transplan-
tation (SPK), pancreas after kidney transplantation (PAK),
and pancreas transplantation alone (PTA) [15]. Before pan-
creas transplantation, these patients usually present other
microvascular complications derived from their DM, gener-
ally in an advanced stage such as CAN [7]. Successful pan-
creas transplantation achieves long-term normoglycemia
and allows the assessment of the effect of prolonged nor-
malization of the glucose metabolism on the course of dia-
betic complications including severe forms of diabetic
neuropathy [16].
However, the data currently available on the improve-
ment of neuropathy of pancreas-kidney transplant patients
is limited, and there are doubts about the chronological evo-
lution after transplantation [16–19]. To the best of our
knowledge, no study has so far indicated which CART is first
modified after pancreas transplantation.
This report describes the results of clinical examination
and autonomic function tests in patients with T1DM before
and up to 10 years after successful SPK transplantation.
2. Methods
2.1. Patients. This is a prospective study of 81 patients
with T1DM (48 males and 33 females, mean age 37:4 ± 5:7
years, mean BMI 24:0 ± 3:4 kg/m2, and mean duration of
diabetes 25:5 ± 6:5 years) who received SPK transplantation,
at La Fe University Hospital in Valencia (Spain), between
2002 and 2015.
The inclusion criteria for SPK transplantation were T1DM
patients (C − peptide < 0:5 ng/mL), end-stage renal disease
(glomerular filtration rate < 20mL/min/1:73m2), below 50
years of age, with absence of severe psychiatric or psychological
disorders and ability to understand what a pancreas transplan-
tation entails in relation to postoperative collaboration, and
complications that may arise in the follow-up of treatment.
After SPK transplantation, the maintenance of the func-
tion of the pancreatic graft and renal graft was defined as
the achievement of complete independence from insulin
and dialysis, respectively. Renal graft loss was considered as
the need for dialysis after transplantation. Pancreas graft loss
was considered; when after the transplantation, the graft had
a partial function that required the use of exogenous insulin;
when it presented a rejection, T1DM recurrence or a pancre-
atectomy was performed due to surgical complications
(Figure 1). After SPK transplantation, 4 patients required
nephrectomy due to surgical complications; these patients
also suffered pancreatic function loss requiring exogenous
insulin and, therefore, were not selected for the study.
After SPK transplantation, 56 patients retained pancre-
atic graft: 14 of them required low doses of insulin therapy,
0.25UI/kg/day, and 42 presented normofunctioning pan-
creas without exogenous insulin (Figure 1).
Demographical, clinical, and biochemical data were col-
lected in these 42 patients.
2.2. Transplantation Procedure. Our transplantation proce-
dure has been previously described [20].
2.2.1. Surgical Technique. All pancreas transplantations were
performed by the same surgical team. All pancreatic and kid-
ney grafts were procured from deceased donors, and both
were placed extraperitoneally.
2.2.2. Immunosuppression. Antithymocyte globulin or basi-
liximab were used for induction immunosuppression ther-
apy. As maintenance immunosuppression therapy, patients
are currently treated with a combination therapy consisting
of tacrolimus, mycophenolate mofetil or sirolimus, and
prednisone.
2.3. Laboratory Methods. Biochemical parameters were eval-
uated with different laboratory techniques. Serum glucose,
urea, creatinine, total cholesterol, high-density lipoprotein
cholesterol (HDL-c), and triglycerides levels were measured
by enzymatic and colorimetric techniques (Cobas c701;
ROCHE/HITACHI).
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C-peptide serum levels were measured using an electro-
chemiluminescence immunoassay (Cobas c602).
Glycated hemoglobin (HbA1c) was measured using
high-performance liquid chromatography (HPLC) (Horiba
Tosoh G11).
The glomerular filtration rate (GFR) was calculated from
serum creatinine levels using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation.
Finally, estimated low-density lipoprotein cholesterol
(LDL-c) was calculated using Friedewald’s equation.
2.4. Neurological Evaluation. Neurological evaluation was
made before SPK transplantation and during follow-up: after
3, 5, 7, and 10 years. Autonomic function was assessed using
CARTs that measure systolic blood pressure (SBP) responses
to standing up and HR responses to the Valsalva maneuver
and to deep breathing [21–23]. All CARTs were performed
after an appropriate wash out (24 hours) of the antihyperten-
sive treatment.
Expiration/inspiration (E/I) or deep breathing ratio
assesses HR variability induced by a series of deep breath-
ing cycles. This test is based on the fact that the HR
decreases during expiration and increases during inspira-
tion. With the patient at rest and supine for at least 10
minutes, HR is monitored by electrocardiogram (ECG)
while the patient performs 6 deep breathing cycles, one
breath every 10 seconds. The quotient between the longest
R-R during expiration and the shortest R-R during the
inspiration phase is performed in 3 of the 6 cycles, with
the final result being the average of the 3 determinations.
A difference of >15 beats per minute (bpm) are considered
normal and <10 bpm is abnormal. The lowest normal
value for E/I ratio is variable, and it decreases with age:
age 20-24 years, 1.17; 25-29, 1.15; 30-34, 1.13; 35-39,
1.12; 40-44, 1.10; 45-49, 1.08; 50-54, 1.07; 55-59, 1.06;
60-64, 1.04; 65-69, 1.03; and 70-75, 1.02 [24].
30 : 15 ratio assesses HR response to standing up and con-
sists of an initial increase in HR followed by a decrease in HR.
The patient, after remaining for 3 minutes in a relaxed supine
position, should quickly adopt the standing position in less
than 3 seconds. The ratio of the R-R interval recorded at beat
30 and the R-R interval recorded at beat 15 after taking the
standing position is calculated. The 30 : 15 ratio is variable
and depends on the patient’s age: age 20-29 years, 1.12; 30-
39, 1.10; 40-49, 1.08; 50-60, 1.07; and 61-65, 1.06 [24].
Valsalva ratio assesses HR variability during an increase
in intrathoracic pressure using the Valsalva maneuver. The
Valsalva maneuver is influenced by both, the sympathetic
system and the parasympathetic system [10]. When the
patient is seated, he/she has to blow through a mouthpiece
for 15 seconds, keeping the glottis closed constantly and
continuously, maintaining a resistance of approximately
40mmHg. The ratio between the longest R-R interval after
the maneuver and the shortest R-R interval recorded during
the 15 seconds of forced expiration is calculated. The normal
ratio of the longest to the shortest R-R [24, 25] is also variable
and decreases with age: age 20-29 years, 1.21; 30-39, 1.19; 40-
49, 1.18; 50-60, 1.17; and 61-65, 1.16.
2.4.1. Variation of SBP during Postural Changes. This test
assesses sympathetic function and is performed in the same
maneuver (positional change of supine position to standing)
as the 30/15 ratio, and they are calculated jointly. The patient
has to remain in the supine position for 3 minutes, during
which blood pressure is measured 3 times. Afterwards, the
patient has to adopt the standing position quickly (in less
than 3 seconds). After that, 2 blood pressure measurements
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Figure 1: SPK transplant evolution.
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decubitus and the average of the SBP in standing position is
calculated. Normal response is a fall of SBP of <10mmHg,
borderline is a fall of 10-29mmHg, and abnormal is a fall
of >30mmHg with symptoms [24].
CARTs were performed withNeurotester® (Italy, 2009). All
the previous test values were transferred and processed by a
computer program synchronized with Neurotester®. The nor-
mality values were adjusted according to the patient’s age.
The result of each test will be as follows: normal, borderline
(or prephatological), or pathological. According to the Ameri-
can Diabetes Association (ADA) and the American Academy
of Neurology recommendations, at least 2 abnormal HR tests
are required for a confirmed diagnosis of CAN [3, 14, 26, 27].
2.5. Data Analysis. Continuous variables were described using
mean and interquartile range for baseline and follow-up patient
characteristics, and the mean and standard deviation for
CARTs. Categorical values were summarized as proportions.
With respect to the statistical analysis, a paired two-tailed
t-test was used for comparing results over time within each
group for continuous variables. The Pearson test was used
for categorical variables. When the available observations
were limited, the Fischer exact test was used.
The level of significance was p < 0:05 for all the tests.
Statistical analyses were performed using SPSS Statistics®
(version 20). The Benjamini-Hochberg Procedure [28] cor-
rection was applied to minimize the likelihood of type 1
Table 1: Paired tests for the baseline and post-SPK follow-up characteristics in SPK recipients.
Parameter Baseline
Follow-up
3 years 5 years 7 years 10 years
















































































































































Patients with hypolipemiant treatment 26 (61.9%) 8 (19.0%)# 5 (11,9%)# 1 (2.4%)nd 1 (2.4%)nd
Patients with antihypertensive treatment 40 (95.2%) 16 (38.1%)# 10 (23.8%)# 4 (9.5%)† 3 (7.1%)†
Patients with beta-blockers treatment 13 (30.9%) 3 (9.7%)† 1 (6.25%)† 0 (0%)† 0 (0%)†
Patients with diagnosis of CAN/patient with CARTs
performed
30/31 (96.8%) 16/16 (100%) 11/13 (84.6%) 5/6 (83.3%) 2/3 (66.7%)
SPK: simultaneous pancreas and kidney transplantation; BMI: body mass index; eGFR: estimated Glomerular Filtration Rate; HDL-C: high-density lipoprotein
cholesterol; LDL-C: low-density lipoprotein cholesterol; CAN: cardiovascular autonomic neuropathy. †p < 0:001, patients at 3, 5, 7, or 10 years after SPK vs
baseline. #p < 0:01, patients at 3, 5, 7, or 10 years after SPK vs baseline. ¤p < 0:05, patients at 3, 5, 7, or 10 years after SPK vs baseline. nd: test not done.
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errors in multiple testing (results were described before and
after the adjustment) with a false discovery rate of 10%.
2.6. Ethical Approval. This study was approved by Comité
Ético de Investigacion Clínica (CEIC) of La Fe Health Research
Institute, Valencia (Spain). This article contains human
studies approved by CEIC. Written informed consent was
obtained from all patients prior to their inclusion in the study.
3. Results
This study included 42 patients with T1DM (25 males and 17
females, with a mean age of 37:6 ± 5:6 years, mean BMI
23:9 ± 3:1 kg/m2, and a mean duration of diabetes 25:2 ±
6:2 years) who had undergone SPK transplantation and
maintained functioning pancreatic and renal grafts during
the follow-up. All patients were dialysis- and insulin-free
and normoglycemic (their glycosylated hemoglobin levels
were normal) at the moment of this study. Baseline and
post-SPK follow-up characteristics are included in Table 1.
Paired tests confirmed a significant improvement, especially
in metabolic endpoints.
All patients achieved good control of arterial pressure,
both at the time of SPK and during the follow-up, with or
without antihypertensive treatment. Other known causes
that could contribute to neuropathy were discarded in
patients both at the time of SPK transplantation and during
the follow-up.
Standard CARTs were used for the evaluation of auto-
nomic neuropathy, on 31 patients before SPK transplanta-
tion, 16 of them again after 3 years, 13 after 5 years, 6 after















































IQR = [–34.25, 17.50]
Baseline / 3-4 years p = 0.280
Baseline / 5-6 years p = 0.030
Baseline / 7-8 years p = 0.690



















































IQR = [1.13, 1.49]
Baseline / 3-4 years p < 0.001
Baseline / 5-6 years p = 0.001
Baseline / 7-8 years p = 0.070































IQR = [1.02, 1.23]
Baseline / 3-4 years p = 0.090
Baseline / 5-6 years p = 0.110
Baseline / 7-8 years p = 0.480



































IQR = [1.02, 1.16]
Baseline / 3-4 years p = 0.080
Baseline / 5-6 years p = 0.260
Baseline / 7-8 years p = 0.690
(d)
Figure 2: Results of cardiovascular function tests in SPK recipients, before and during the follow-up (textbox include paired t-tests). (a)
Systolic blood pressure response to orthostasis. (b) Heart rate response to the Valsalva maneuver. (c) Heart rate response to orthostasis
(30 : 15 ratio). (d) Heart rate variability with deep breathing (E/I). Data shown as median [interquartile range]. Interrupted line indicates
lower limit of normal and borderline values from Sundkvist and Lilja (1985) [21] and Ewing et al. (1985) [23]. SPK: simultaneous
pancreas and kidney transplantation.
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Before the transplant procedure, all tests of autonomic
function revealed abnormal results (Figure 2), obtaining a
high prevalence of CAN: 96.8% (Table 1). After SPK trans-
plantation, prevalence of CAN was progressively reduced
over time (Table 1). Also, after SPK transplantation, paired
patient sample analysis showed an improvement of SBP-
response to orthostasis at the 5th year after SPK (p = 0:03),
as well as improvement of the Vasalva ratio at the 3rd year
(p < 0:001) and the 5th year (p = 0:001) (Table 2).
After applying the Benjamini-Hochberg correction to
multiple testing, the SBP response maintained significance
after the 7th year, and the Vasalva ratio also maintained a
significant improvement after the 7th year and after SPK. In
addition, the 30 : 15 and E/I ratios showed significant
improvement after the 3rd year of the SPK transplantation
(Table 3).
4. Discussion
CAN is a common complication of long-standing diabetes
mellitus. Its etiopathogenesis is multifactorial, but hypergly-
cemia seems to be the primary cause, just as diabetic
nephropathy. Several studies have shown that the longer
the time of evolution of poorly controlled DM, the greater
the complications. Long-term treatment of patients with
short-duration of T1DM with intensive insulin therapy
achieving normoglycemia leads to a reduced CAN prevalence
as well and incidence. In fact, the Diabetes Control and Com-
plication Trial (DCCT) compared an intensive therapy group
versus conventional therapy, and showed that, although
CAN prevalence increased in both groups, the incidence
was significantly lower in the intensively treated group
(28.9% vs 35.2%, p < 0:018) [10]. Also, it should be noted that
intensive insulin therapy increases the risk of hypoglycemia,
which, in turn, worsens CAN [29]. Furthermore, long
periods of normoglycemia are required to retard CAN pro-
gression, and besides, this control is complicated using exog-
enous insulin. For these reasons, pancreas replacement seems
to be the most logical treatment to restore the normoglyce-
mic state in patients with T1DM and related end-stage kid-
ney disease, who are candidates for kidney transplantation.
According to the inclusion criteria, patients undergoing
SPK transplantation present terminal diabetic nephropathy
that requires dialysis programs prior to transplantation.
The pathogenic mechanisms that lead to diabetic nephropa-
thy are the same that may produce diabetic retinopathy and
neuropathy. Therefore, these patients would be expected to
present retinopathy and diabetic neuropathy. In fact, diabetic
neuropathy is very common and severe among candidates
for SPK transplantation [7].
In our study, at baseline, all patients presented abnormal
results in all CARTs. Mean time of evolution of T1DM was
25 years, and glycemic control was not optimal, according
to ADA recommendations, with an HbA1C mean: 8.1%
[14]. Therefore, it would be expected to find microvascular
complications derived from DM such as CAN in this group
of patients.
After pancreas transplantation, a slight improvement in
cardiovascular autonomic function has been demonstrated
in previous studies [18, 19]. Some of them reported that
improvement of CAN seems to be slower and more progres-
sive than the improvement of the peripheral neuropathy.
However, Hathaway et al. [30] reported data from 23 recipi-
ents undergoing SPK and compared them with 16 patients
undergoing kidney transplantation alone (KTA) followed
for 12 months, and showed an improvement in autonomic
nervous function already 1 year after transplantation for both
groups of transplant recipients.
Our prospective 10-year study shows that cardiovascular
autonomic function improves significantly after SPK trans-
plantation. CARTs were analyzed individually using aged-
stratified levels, as reflected in the Methods section. However,
in Figure 2, normal values were considered according to
Sundkvist and Lilja [21] and Ewing et al. (1985) [23], and
reflected as an interrupted line, in order to facilitate the read-
ing of the figure.
The patient population was analyzed using descriptive
statistics and paired tests. Mean values of the observed vari-
ables (analytical and functional tests) for each time period
were compared with the preoperative values (baseline).
Paired patient sample analysis showed that the Valsalva
ratio and SBP response to orthostasis improved statistically
at the 3th and 5th year after SPK, respectively. The E/I ratio
and the 30 : 15 ratio did not reach significance for paired
patient samples.
To reduce the chances of false discoveries in this multiple
testing, the Benjamini-Hochberg correction [28] was applied
to the results of the paired tests. After SPK transplantation
and assuming a 10% of false discovery rate, the corrected tests
showed an improvement of all cardiovascular function tests,
but at different time points. The tests which showed an earlier
improvement were Valsalva and 30 : 15 ratios and E/I ratio,
as statistically significant differences were already found 3
years after SPK. However, these differences were maintained
until 10 years after SPK only in the Valsalva ratio, and the
SBP-response to orthostasis only reached statistical signifi-
cance 5 years and 7 years post-SPK.
In the early stages, CAN may be completely asymptom-
atic and is detected only by a decrease in HR variability, sub-
sequently leading to a clinical form characterized by resting
tachycardia and exercise intolerance. In the most severe
cases, it is accompanied by orthostatic hypotension [24, 26].
SPB response to orthostasis is, therefore, likely to be the last
test to improve after SPK transplantation.
Regarding the sample size, in the basal period the inter-
quartile range is lower than in the later periods, probably
due to a larger sample size. However, attending SPS response
to orthostasis, the interquartile range is higher in the basal
period than in the 3rd-4th and 5th-6th year after SPK. This
could be the reason why SBP-response to orthostasis does
not reach statistical significance 3 years after transplantation.
In all tests evaluated, the number of observations made in
the 7th-8th and 9th-10th periods are not enough to draw a con-
clusion; hence, the great dispersion of the data is obtained.
Additionally, the authors have previously considered the
development models for the assessment of the risk of SPK
transplantation [31], in which predictors were selected on
the basis of their contribution to the outcome, and subjects
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were grouped using supervised and unsupervised classifica-
tion. Nevertheless, due to the hierarchical nature of the data
collected in this study, future work will focus on the develop-
ment of generalized linear mixed models (aggregating data
point for each time interval and considering random effects).
Also, uremia and calcineurin inhibitors (CNI) as causes
of neuropathy should be considered. Both diabetes and
uremia contribute to the nerve dysfunction seen in uremic
diabetic patients. After SPK transplantation, an initial
improvement of neuropathy was probably due to the elimi-
nation of uremia. Subsequently, an additional improvement
of the neuropathy was observed, which could be due to the
repair and regeneration of the nerves. This late improvement
was not seen in diabetic patients who had only undergone
KTA. In our study, all patients underwent SPK transplanta-
tion. Uremia levels were high at the moment of SPK but
decreased after SPK (Table 1).
CNI produce an abnormal nerve function, specifically
reflecting nerve membrane depolarization [32]. For this
reason, neuropathy is a highly prevalent complication in
patients receiving CNI treatment. However, all our patients
were treated with the same maintenance immunosuppres-
sion schedule, with no differences between them with regard
to immunosuppression.
On the other hand, a meta-analysis of 15 longitudinal
studies showed an association between CAN and increased
mortality [3]. This risk has also been demonstrated by sev-
eral studies. Silent myocardial ischemia is present in 20%
of patients with CAN, compared to 10% in patients with-
out CAN [33]. Furthermore, CAN is associated with a
Table 2: Results of cardiovascular autonomic tests, comparing evolution before and after SPK transplantation in paired patient samples.
Statistically results (p < 0:05) are marked in bold.
Test Comparison periods
Statistics Correlations Test





0.11 0.68 -1.13 0.28




0.52 0.04 -2.36 0.03




-0.89 0.11 0.45 0.69




-0.89 0.30 -0.71 0.55





0.49 0.05 -3.46 0.00




0.52 0.03 -5.39 0.00




0.92 0.03 -2.41 0.07




0.87 0.33 -2.79 0.11
9th-10th year 1.36 0.22 0.13




0.35 0.18 -1.83 0.09




0.05 0.85 -1.72 0.11




-0.72 0.17 -0.78 0.48




-0.84 0.36 -1.34 0.31





0.77 0.00 -1.98 0.08




0.70 0.01 -1.20 0.26




1.00 0.00 0.52 0.69
7th-8th year 1.06 0.02 0.01
SBP: systolic blood pressure response to orthostasis; 30 : 15 ratio: heart rate response to orthostasis; E/I ratio: expiration/inspiration or deep breathing ratio;
SPK: simultaneous pancreas kidney transplantation.
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higher risk of peri- and intraoperative cardiovascular com-
plications [5, 6, 12]. This could be due to the fact that
CAN predisposes to life-threatening arrhythmias and sud-
den death [34] and is also associated with ventricular dys-
function [6, 35]. In this sense, the Detection of Ischemia in
Asymptomatic Diabetic Subjects (DIAD) study showed that
a decrease of the Valsalva ratio was associated with silent
myocardial ischemia [36]. Also, CAN predicts the progres-
sion of diabetic nephropathy [37].
Consequently, CAN is considered an independent risk
factor for mortality [37] and the strongest risk factor for all
causes of mortality [3, 38–40].
CAN treatment is generally focused on alleviating symp-
toms [14]. But nevertheless, if the long-term normoglycemia
induced by SPK transplantation can improve the CART
results, SPK transplantation would reduce mortality and
improve the prognosis of diabetic patients with CAN. Pro-
spective studies would be needed to confirm this assumption.
This study has two main limitations. The first one is the
limited sample size. If the sample size was larger, statistically
significant results would probably be achieved in all evalu-
ated periods. Despite this, the differences in CART results
were enough to achieve statistical significance with nonpara-
metric tests in some time periods. The second one is that, in
our study, we did not follow a control group of diabetic
patients not treated with SPK transplantation such as dia-
betic patients treated only with insulin therapy or diabetic
patients undergoing KTA. With a control group of diabetic
patients treated only with KTA, the effect of uremia on neu-
ropathy could have been evaluated.
In conclusion, the prevalence of cardiovascular auto-
nomic neuropathy in candidates for SPK transplantation is
high and is generally advanced. Successful SPK transplanta-
tion normalizes blood glucose, glycosylated hemoglobin,
and uremic levels, and improves CAN. Valsalva ratio is the
most precocious test. Studies with a larger sample size would
be required to confirm our data.
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